Obinutuzumab and low-dose steroids for new kidney disease
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a new diagnosis of ANCA-associated vasculitis (a condition where the immune system attacks small blood vessels), specifically a type called GPA or MPA.
- Your blood test must be positive for one of the ANCA antibodies (called PR3 or MPO).
- Your kidneys must be actively affected, shown by a recent kidney biopsy or by signs of blood and protein in your urine.
- You must not have had prior treatments for this condition with certain medications, such as rituximab, cyclophosphamide, azathioprine, or mycophenolate.
- You must not currently need dialysis or have had dialysis in the past.
- You must not have other serious complications of vasculitis (like bleeding in the lungs, respiratory failure, bowel perforation, or brain involvement), a recent cancer, other autoimmune diseases, active infections, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
This trial tests if adding avacopan, a medication that helps calm the immune system, to usual treatment can improve kidney function in people with a type of blood vessel inflammation called vasculitis that affects the kidneys. It's for people with severe kidney involvement who are starting standard treatment.
This study compares two ways of managing ANCA-associated vasculitis (inflammation of blood vessels) when ANCA antibodies reappear after remission. One approach is close monitoring with blood tests, and the other is giving rituximab infusions right away to prevent a flare-up. It aims to find out which strategy better prevents disease relapse.
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
This trial tests lower steroid doses for people with certain types of vasculitis that have newly affected their kidneys. The goal is to find out if a lower dose works just as well with fewer side effects.
Hear when a new ANCA-Associated Glomerulonephritis (AAGN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.